Cytokinetics (CYTK) Fundamental Analysis: Revenue, Earnings & Valuation

1.26 / 10

Underperform

Fundamentally, CYTK rates Underperform with a 1.3/10 score. Interest coverage (35.1) and inventory turnover (103.9) are decent, yet long‑term debt to working capital (2.63) and PB‑ROE (4.25) are weak, leading to a prudent outlook.

Analysis Checks(6/10)

Revenue-MV

Value-3.80

Score1/3

Weight45.71%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value376.56

Score2/3

Weight1.26%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-10.50%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value9.71

Score3/3

Weight17.10%

1M Return1.67%

PB-ROE

Value4.25

Score0/3

Weight31.01%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value2.63

Score1/3

Weight-6.19%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-10.67%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value376.56

Score2/3

Weight0.51%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-10.09%

1M Return-1.13%

Asset-MV

Value-0.55

Score0/3

Weight41.84%

1M Return4.00%

Is CYTK fundamentally strong?

CYTK scores 1.26/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -891.60% net margin, -9.81 P/E ratio, -11.67 P/B ratio, and -24.33% earnings growth, these metrics solidify its Underperform investment rating.